Home › Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma clinical trials recruiting in the U.S.
14 studies for Nasopharyngeal Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Atlanta, GA6 studies
- Washington, DC4 studies
- Oklahoma City, OK3 studies
- Milwaukee, WI3 studies
- San Francisco, CA3 studies
- Los Angeles, CA3 studies
- Chicago, IL3 studies
- Houston, TX3 studies
- Charlotte, NC3 studies
- Cincinnati, OH3 studies
- Richmond, VA3 studies
- Pittsburgh, PA3 studies
By state
- California6 studies
- Georgia6 studies
- Illinois3 studies
- Maryland4 studies
- Missouri3 studies
- New Jersey3 studies
- New York4 studies
- North Carolina3 studies
- Ohio3 studies
- Oklahoma3 studies
- Pennsylvania3 studies
- South Carolina3 studies
- Texas4 studies
- Virginia4 studies
- Wisconsin3 studies
Recently updated studies
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07667400Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06029270Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06980038A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 2
Up to age 21 · All sexes · Updated Oct 14, 2026 · NCT06064097A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07749586Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03010150[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 6, 2026 · NCT06479811Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Recruiting
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06662058Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
Recruiting
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT01365169Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06592599Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Recruiting
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06682442TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT06636734From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.